Back to resultsEfficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Primary Purpose
Pulmonary Sarcoidosis
Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Efzofitimod 3 mg/kg
Efzofitimod 5 mg/kg
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Pulmonary Sarcoidosis focused on measuring Pulmonary Sarcoidosis, Sarcoidosis, Granuloma, Inflammation, Lymphoproliferative Disorders, Interstitial Lung Disease, Neuropilin-2, Steroids, Oral corticosteroids, Immunomodulatory, tRNA Synthetase, ATYR1923, KRP-R120, Efzofitimod, Fibrosis
Eligibility Criteria
Inclusion Criteria:
- Confirmed diagnosis of pulmonary sarcoidosis for at least 6 months, defined by the following criteria: documented histologically proven diagnosis of sarcoidosis by tissue biopsy and documented evidence of parenchymal lung involvement by historical radiological evidence
- Evidence of symptomatic pulmonary sarcoidosis, as demonstrated by the following criteria: Modified Medical Research Council (MRC) dyspnea scale grade of at least 1 and KSQ-Lung score ≤70
- Patients must be receiving treatment with OCS of ≥ 3 months with a starting dose between ≥ 7.5 and ≤ 25 mg/day.
- Body weight ≥ 40 kg and < 160 kg
Exclusion Criteria:
- Treatment with > 1 oral immunosuppressant therapy
- Treatment with biological immunomodulators, such as tumor necrosis factor-alpha (TNF-α) inhibitors or antifibrotics or interleukin inhibitors
- Likelihood of significant pulmonary fibrosis as shown by any 1 or more of the following: High resolution CT fibrosis > 20% at Screening; FVC % predicted < 50% and KSQ-Lung score < 30
- Clinically significant pulmonary hypertension requiring treatment with vasodilators
- Patients with cardiac sarcoidosis, neurosarcoidosis, or renal sarcoidosis
- Clinically significant cutaneous and ocular sarcoidosis
- History of Addisonian symptoms that precluded previous OCS taper attempts
- Is an active, heavy smoker of tobacco/nicotine-containing products
- History of anti-synthetase syndrome or Jo-1 positive at baseline
Sites / Locations
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative Site
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative Site
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- Kyorin Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
- aTyr Investigative SiteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Efzofitimod 3 mg/kg
Efzofitimod 5 mg/kg
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in mean daily oral corticosteroid (OCS) dose post-taper
Secondary Outcome Measures
Annual rate of change in absolute value of Forced vital capacity (FVC)
Percent change from baseline in mean daily OCS dose post-taper
Change from baseline in King's Sarcoidosis Questionnaire (KSQ)-Lung score
Full Information
NCT ID
NCT05415137
First Posted
June 8, 2022
Last Updated
September 6, 2023
Sponsor
aTyr Pharma, Inc.
Collaborators
Kyorin Pharmaceutical Co.,Ltd
1. Study Identification
Unique Protocol Identification Number
NCT05415137
Brief Title
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Official Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 15, 2022 (Actual)
Primary Completion Date
December 15, 2024 (Anticipated)
Study Completion Date
January 15, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
aTyr Pharma, Inc.
Collaborators
Kyorin Pharmaceutical Co.,Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Sarcoidosis
Keywords
Pulmonary Sarcoidosis, Sarcoidosis, Granuloma, Inflammation, Lymphoproliferative Disorders, Interstitial Lung Disease, Neuropilin-2, Steroids, Oral corticosteroids, Immunomodulatory, tRNA Synthetase, ATYR1923, KRP-R120, Efzofitimod, Fibrosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
264 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Efzofitimod 3 mg/kg
Arm Type
Experimental
Arm Title
Efzofitimod 5 mg/kg
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Efzofitimod 3 mg/kg
Other Intervention Name(s)
ATYR1923, KRP-R120
Intervention Description
EfzofitimodIV infusion every 4 weeks for a total of 12 doses
Intervention Type
Drug
Intervention Name(s)
Efzofitimod 5 mg/kg
Other Intervention Name(s)
ATYR1923, KRP-R120
Intervention Description
EfzofitimodIV infusion every 4 weeks for a total of 12 doses
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo IV infusion every 4 weeks for a total of 12 doses
Primary Outcome Measure Information:
Title
Change from baseline in mean daily oral corticosteroid (OCS) dose post-taper
Time Frame
Baseline to Week 48
Secondary Outcome Measure Information:
Title
Annual rate of change in absolute value of Forced vital capacity (FVC)
Time Frame
Baseline to Week 48
Title
Percent change from baseline in mean daily OCS dose post-taper
Time Frame
Baseline to Week 48
Title
Change from baseline in King's Sarcoidosis Questionnaire (KSQ)-Lung score
Time Frame
Baseline to Week 48
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Confirmed diagnosis of pulmonary sarcoidosis for at least 6 months, defined by the following criteria: documented histologically proven diagnosis of sarcoidosis by tissue biopsy and documented evidence of parenchymal lung involvement by historical radiological evidence
Evidence of symptomatic pulmonary sarcoidosis, as demonstrated by the following criteria: Modified Medical Research Council (MRC) dyspnea scale grade of at least 1 and KSQ-Lung score ≤70
Patients must be receiving treatment with OCS of ≥ 3 months with a starting dose between ≥ 7.5 and ≤ 25 mg/day.
Body weight ≥ 40 kg and < 160 kg
Exclusion Criteria:
Treatment with > 1 oral immunosuppressant therapy
Treatment with biological immunomodulators, such as tumor necrosis factor-alpha (TNF-α) inhibitors or antifibrotics or interleukin inhibitors
Likelihood of significant pulmonary fibrosis as shown by any 1 or more of the following: High resolution CT fibrosis > 20% within the last 12 months; FVC percent predicted (FVCPP) < 50% and KSQ-Lung score < 30
Clinically significant pulmonary hypertension requiring treatment with vasodilators
Patients with cardiac sarcoidosis, neurosarcoidosis, or renal sarcoidosis
Clinically significant cutaneous and ocular sarcoidosis
History of Addisonian symptoms that precluded previous OCS taper attempts
Is an active, heavy smoker of tobacco/nicotine-containing products
History of anti-synthetase syndrome or Jo-1 positive at baseline
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
aTyr Pharma Clinical Research
Phone
877-215-5731
Email
clinicaltrials@atyrpharma.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Carey
Organizational Affiliation
aTyr Pharma, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
aTyr Investigative Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Valencia
State/Province
California
ZIP/Postal Code
23823
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80206
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30342
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
877-596-6699
Email
efzofit@cssi.enroll.com
Facility Name
aTyr Investigative Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Ada
State/Province
Michigan
ZIP/Postal Code
49301
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55445
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
38216
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Albany
State/Province
New York
ZIP/Postal Code
12208
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Greenville
State/Province
North Carolina
ZIP/Postal Code
27834
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97220
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425-0630
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Dickson
State/Province
Tennessee
ZIP/Postal Code
37055
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37204
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84108
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Falls Church
State/Province
Virginia
ZIP/Postal Code
22042
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Bobigny
ZIP/Postal Code
93000
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
8775966699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
La Tronche
ZIP/Postal Code
38700
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Montpellier
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Paris
ZIP/Postal Code
75015
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Florence
ZIP/Postal Code
50134
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Forlì
ZIP/Postal Code
47121
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Padua
ZIP/Postal Code
35128
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Siena
ZIP/Postal Code
53100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
Kyorin Investigative Site
City
Aomori
ZIP/Postal Code
036-8563
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Fukuoka
ZIP/Postal Code
814-0180
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Hokkaido
ZIP/Postal Code
060-0033
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Hokkaido
ZIP/Postal Code
060-8648
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Hyōgo
ZIP/Postal Code
653-0013
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Kanagawa
ZIP/Postal Code
236-0004
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Kanagawa
ZIP/Postal Code
236-0051
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharm.co.jp
Facility Name
Kyorin Investigative Site
City
Miyagi
ZIP/Postal Code
980-8574
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Okayama
ZIP/Postal Code
700-8558
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Osaka
ZIP/Postal Code
591-8025
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Shimane
ZIP/Postal Code
693-8501
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Shizuoka
ZIP/Postal Code
431-3192
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Tochigi
ZIP/Postal Code
329-0498
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Tokyo
ZIP/Postal Code
150-8935
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
Phone
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
Kyorin Investigative Site
City
Tokyo
ZIP/Postal Code
151-8528
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
+81-3-3525-4788
Email
ml-kyorin_clinicaltrials.gov@mb.kyorin-pharma.co.jp
Facility Name
aTyr Investigative Site
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Eindhoven
ZIP/Postal Code
5623 EJ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Nieuwegein
ZIP/Postal Code
3435CM
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Barcelona
ZIP/Postal Code
08907
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Madrid
ZIP/Postal Code
28031
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
877-596-6699
Email
efzofit@cssi.enroll.com
Facility Name
aTyr Investigative Site
City
Santander
ZIP/Postal Code
39008
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Birmingham
ZIP/Postal Code
B15 2GW
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
Cambridge
ZIP/Postal Code
CB233RE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
877-596-6699
Email
efzofit@cssi.enroll.com
Facility Name
aTyr Investigative Site
City
Cottingham
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
Facility Name
aTyr Investigative Site
City
London
ZIP/Postal Code
SE59RS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
877-596-6699
Email
efzofit@cssienroll.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
We'll reach out to this number within 24 hrs